MRT 5413
Alternative Names: MRT-5413; Quadrivalent influenza mRNA vaccineLatest Information Update: 24 May 2024
Price :
$50 *
At a glance
- Originator Sanofi Pasteur
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza virus infections
Most Recent Events
- 02 Apr 2024 Sanofi Pasteur completes a phase I/II trial in Influenza virus infections (Prevention) in Puerto Rico, Australia and USA (IM) ((NCT05650554)
- 06 Dec 2022 Phase-I/II clinical trials in Influenza virus infections (Prevention) in USA (IM) (NCT05650554; VAV00029)